The Effectiveness of GABA Agonist in Decreasing Expression of NR2B Subunit of N-Methyl-D-Aspartate (NMDA) Receptor in Neuropathic Mice by Partial Sciatic Nerve Ligation (PSNL) Method
Neuropathy pain is a pain that caused by nerves injury. Nowadays, treatment for neuropathic pain change to drugs that works as GABA agonist and cause reimbalance between excitatory and inhibitory neurotransmitter in central nervous system (CNS). The present study was designed to investigate the effectiveness of gabapentin and baclofen in decreasing N-Methyl-D-Aspartate (NMDA) receptor NR2B subunit activity in neuropathic pain. Fourty mice were divided into 8 groups i.e sham, negative control, gabapentin (10, 30, 100 nmol) and baclofen (1, 10, 30 nmol). Neuropathic pain was induced by ligation of sciatic nerve with Partial Sciatic Nerve Ligation (PSNL) method). Treatments were administrated intrathecally once a day for seven consecutive days, at a week after induction. On day 15th, mice were sacrified and the spinal cord were removed quickly. The expression of NMDA receptor NR2B subunit were examined with imunohistochemistry and data were analyzed by one way anova. The result from this research was gabapentin and baclofen administration significantly decrease expression of NMDA receptor NR2B subunit in mice compared to sham group. The higher the dose, the more effective to decrease the number of neuron that express NR2B. The conclusion of this research was gabapentin and baclofen treat neuropatic pain by decreased the number of NMDA receptor NR2B subunit.
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
copy and redistribute the article in any medium or format
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
- NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.